Vol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
|
|
- Aileen Haynes
- 5 years ago
- Views:
Transcription
1 25 Vol. 36, pp , 2008 T1-3N0M0 : T1-3 N0M Gy 68 Gy 24 prostate-specific antigen PSA p 0.04 T3 PSA60 ng ml 68 Gy p Cox PSA60 ng ml 68 Gy 68 Gy 68 Gy 1987 National Institutes of Health
2 26 prostatespecific antigen PSA T1-3N0M0 113 retrospective Table UICC T T1: 17 T2: 48 T3: 48 Gleason GS 4 : 18 GS5-7: 76 GS8-10: 19 PSA ng ml 19ng ml 10ng ml: ng ml: ng ml: 30 60ng ml: 23 1 T PSA T1 2 PSA 10 GS 7 T3 PSA 20 GS cm 7 7cm cm X CT X ml ml : : 64 0 Table 1. Patient Characteristics 10MV-X Gy Gy 68Gy Gy Gy
3 LH-RH : 103 : 5 : PSA PSA Kaplan-Meier PSA Gy 24 2 T T1-T2 T3 PSA 60ng ml - 2 log-rank Cox 5 R version2.6.1 National Cancer Institute- Common Toxicity Criteria 1998 Fig. 1. Overall OS and disease-specific survival DSS for all patients Fig p Fig. 2 T 5 T1-2 T p Fig. 3 PSA 5 60ng ml 60ng ml p 0.03 Fig. 4 PSA60ng ml 20ng ml 20 59ng ml 5 Fig. 2. Disease-specific survival by risk category. Fig. 3. Disease-specific survival by T stage. 27
4 28 Fig. 4. Disease-specific survival by initial prostatespecific antigen 60ng ml vs. 60ng ml. Fig. 5. Disease-specific survival by total dose 68 Gy vs. 68Gy Gy 68Gy p 0.04Fig. 5 T PSA T1 2 T PSA60ng ml 5.0 p Gy 0.16 p 0.03 Table 2 n Gy 0.2 p 0.04 Table 3 Table 2. Results of Univariate and Multivariate Analysis for Disease-specific Survival of All Patients 28
5 29 Table 3. Results of Univariate and Multivariate Analysis for Disease-specific Survival of High-risk Patients grade grade2 1.7 T PSA PSA60 ng ml 68 Gy 68 Gy PSA Roach 5 20 ng ml PSA PSA 6 PSA T GS 60 ng ml PSA 60 ng ml PSA ng ml Gy Swanson 7 60 Gy A: 9 B: 93 C: Gy Gy Akakura Gy Gy 29
6 30 70 Gy 70 Gy CT 74 Gy T1-3N0M0 113 retrospective PSA60 ng ml 68Gy. 68 Gy. grade The management of clinically localized prostate cancer, National Institutes of Health Consensus Development Conference, June 15 17, J Uro 1987; 138: Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimano# RO, Storme G, Bernier J, Kuten A, Sternberg C, Matterlaer J, Lopez Torecilla J, Pfe#er JR, Lino Cutajar C, Zurlo A and Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer an EORTC study : a phase III randomised trial. Lancet 2002; 360: Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM and Shipley WU. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol J Clin Oncol 2003; 21: Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N and Niibe H. External beam radiotherapy for clinically node-negative, localized hormonerefractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 2004; 59: Roach M 3rd, Weinberg V, McLaughlin PW, Grossfeld G and Sandler HM. Serum prostatespecific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology 2003; 61: Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: Swanson GP, Riggs MW and Earle JD. Longterm follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, Hirano D, Takimoto Y, Kamoto T, Ogawa O, Sumiyoshi Y, Shimazaki J, Kakizoe T and the Japanese Study Group for Locally Advanced Prostate Cancer. A randomized trial comparing radical prostatectomy plus endocrine therapy versus exter- 30
7 31 nal beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006; 36: Vicini FA, Abner A, Baglan KL, Kestin LL and Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better?. Int J Radiat Oncol Biol Phys 2001; 51: Speight JL and Roach M. Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005; 23: Leibel SA, Fuks Z, Zelefsky MJ, Hunt M, Burman CM, Mageras GS, Chui CS, Jackson A, Amols HI and Ling CC. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol 2003; 30: Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG and Pollack A. Role of prostate dose escalation in patients with greater than 15 risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005; 61:
8 32 Abstract Therapeutic Results and Prognostic Factors in Patients with T1-3N0M0 Prostate Cancer Treated by Definitive External-Beam Radiotherapy Combined with Hormonal Therapy Tatsuyuki Abe, Hiromichi Gomi, Shinjiro Sakaino, and Yasuo Nakajima When considering treatment strategy, it is very important to evaluate the prognostic factors for overall survival OS and disease-specific survival DSS in patients with prostate cancer treated by external-beam radiotherapy combined with hormonal therapy. The purpose of this study was to evaluate the treatment and to determine these prognostic factors in patients with T1-3N0M0 prostate cancer treated by definitive external beam radiotherapy combined with hormonal therapy. In total, we studied 113 of these patients between 1990 and The median total dose of radiation was 68Gy and the median duration of hormonal therapy was 24 months range, 2 to 134 months. Risk groups were defined as follows: low-risk, T1 2 and Gleason score 7, or well di#erentiated and PSA 10ng ml; high-risk, T3 or Gleason score 7 or poorly di#erentiated or PSA 20ng ml; intermediate-risk, all others. Follow-up ranged from 1,2 to 17.2 years median, 6.5 years. Clinicopathologic factors a#ecting OS and DSS were univariately and multivariately analyzed. For all patients, 5-year OS and DSS rate were 91 and 95 respectively. The 5-year DSS rate by risk group was 100 for the low- and intermediate-risk groups and 93 for the high-risk group p Univariate analysis showed that higher grade of T-factor, greater initial PSA value and higher total dose were significantly associated with poorer DSS p , 0.03, and 0.04 respectively. Multivariate analysis showed that initial PSA value 60ng ml and total dose 68Gy were significantly associated with poorer DSS. In addition, among high-risk patients, total dose 68Gy was significantly associated with DSS. Since the DSS of patients with high-risk prostate cancer is significantly worse, we suggest that total dose 68Gy is needed for treatment of high-risk prostate cancer. Department of Radiology, St. Marianna University School of Medicine 32
The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials
British Journal of Cancer (2004) 90, 950 954 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Minireview The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective
More informationProject approved by the Fondo de investigaciones Socio Sanitarias (FISS). Resolution dated June 8, Official State Gazette: June 17, 2004.
Edition No. 01 Phase III randomized and multicenter trial of adjuvant androgen deprivation combined with high-dose 3-dimensional conformal radiotherapy in intermediate- or high-risk localized prostate
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer
ONCOLOGY LETTERS 10: 255-259, 2015 Impact of the duration of hormonal therapy following radiotherapy for localized prostate cancer MITSURU OKUBO, HIDETUGU NAKAYAMA, TOMOHIRO ITONAGA, YU TAJIMA, SACHIKA
More informationAn examination of existing trial data on the treatment of prostate cancer using external beam radiotherapy combined with hormone therapy.
1.0 Introduction. An examination of existing trial data on the treatment of prostate cancer using external beam radiotherapy combined with hormone therapy. Professor L.J.S.Bradbury Ph.D. For low or intermediate
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationANTICANCER RESEARCH 34: (2014)
Role of Novel Risk Classification Method, Prostate Cancer Risk Index (PRIX) for Clinically Localized Prostate Cancer Αfter High-dose-rate Interstitial Brachytherapy as Monotherapy KEN YOSHIDA 1, HIDEYA
More informationRadiation dose has been reported to be an important determinant
538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationRadical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report
Jpn J Clin Oncol 2003;33(3)122 126 Original Articles Radical Radiation Therapy for Prostate Cancer in Japan: a Patterns of Care Study Report Katsumasa Nakamura 1, Teruki Teshima 2, Yutaka Takahashi 2,
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationdoi: /j.ijrobp CLINICAL INVESTIGATION
CME doi:10.1016/j.ijrobp.2010.07.2004 Int. J. Radiation Oncology Biol. Phys., Vol. 81, No. 5, pp. 1293 1301, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ - see
More informationSRO Tutorial: Prostate Cancer Clinics
SRO Tutorial: Prostate Cancer Clinics May 7th, 2010 Daniel M. Aebersold Klinik und Poliklinik für Radio-Onkologie Universität Bern, Inselspital Is cure necessary in those in whom it may be possible, and
More informationStrategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer
Strategies of Radiotherapy for Intermediate- to High-Risk Prostate Cancer Daisaku Hirano, MD Department of Urology Higashi- matsuyama Municipal Hospital, Higashi- matsuyama- city, Saitama- prefecture,
More informationProstate Cancer in comparison to Radiotherapy alone:
Prostate Cancer in comparison to Radiotherapy alone: 1 RTOG 86-10 (2001) 456 patients with > a-goserelin 2 month before RTand during RT + Cyproterone acetate (1 month) vs b-pelvic irradiation (50 gy) +
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 4 FEBRUARY 1 28 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationMonotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,
More informationfailure (FBF) rates were calculated using the Phoenix definition.
. JOURNAL COMPILATION 2009 BJU INTERNATIONAL Urological Oncology GLEASON SCORES 8 10 PROSTATE CANCER TREATED WITH TRIMODAL THERAPY STOCK et al. BJUI BJU INTERNATIONAL Outcomes for patients with high-grade
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationRadiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D.
UvA-DARE (Digital Academic Repository) Radiation treatment in prostate cancer : balancing between tumor control and toxicity Heemsbergen, W.D. Link to publication Citation for published version (APA):
More informationRadiotherapy (RT) Protocol for Prostate Cancer
Radiotherapy (RT) Protocol for Prostate Cancer CGMH-2010-02 *This document is aimed to set up RT protocols for prostate cancer. The treatment guideline for prostate cancer will not be covered here. A.
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationdoi: /s (03) CLINICAL INVESTIGATION
doi:10.1016/s0360-3016(03)01746-2 Int. J. Radiation Oncology Biol. Phys., Vol. 58, No. 4, pp. 1048 1055, 2004 Copyright 2004 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/04/$ see front
More informationMOLECULAR AND CLINICAL ONCOLOGY 6: , TEELE KUUSK, KRISTIINA PULLIAINEN and MARKKU H. VAARALA
428 External beam radiation for the treatment of castration resistant prostate cancer following primary hormonal therapy with androgen ablation: Analysis and outcome of 21 patients TEELE KUUSK, KRISTIINA
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationOutcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution Experience
european urology 51 (2007) 121 129 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Outcome of Surgery for Clinical Unilateral T3a Prostate Cancer: A Single-Institution
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationUpdated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy for Locally and Locally Advanced
Clinical Urology High-Dose Rate Brachytherapy for Prostate Cancer International Braz J Urol Vol. 34 (3): 293-301, May - June, 2008 Updated Results of High-Dose Rate Brachytherapy and External Beam Radiotherapy
More informationThe Central Role of Radiation in Prolonging Survival for High-Risk Prostate Cancer
The Central Role of Radiation in Prolonging Survival for High-Risk Prostate Cancer Dean A. Shumway, MD, and Daniel A. Hamstra, MD, PhD Abstract Prostate cancer represents a leading cause of cancer mortality
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationOutcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy in Indonesia
Original Article Prostate Int 2013;1(1):16-22 http://dx.doi.org/00.0000/apps.2013.1.1 P R O S T A T E INTERNATIONAL Outcomes and predictors of localized or locally-advanced prostate cancer treated by radiotherapy
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationNIH Public Access Author Manuscript Int J Radiat Oncol Biol Phys. Author manuscript; available in PMC 2012 June 1.
NIH Public Access Author Manuscript Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 June 1; 80(2): 445 452. doi:10.1016/j.ijrobp.2010.02.034. Impact of ultrahigh baseline PSA levels
More informationMultimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their combination
Review Article Radiat Oncol J 2017;35(3):189197 pissn 22341900 eissn 22343156 Multimodal therapy for locally advanced prostate cancer: the roles of radiotherapy, androgen deprivation therapy, and their
More informationMichael J. Zelefsky MD a,, W. Robert Lee MD b, Anthony Zietman MD c, Najma Khalid MS d, Cheryl Crozier RN d, Jean Owen PhD d, J.
Practical Radiation Oncology (2013) 3, 2 8 www.practicalradonc.org Original Report Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality
More informationMichelle S Ludwig 1*, Deborah A Kuban 2, Xianglin L Du 4, David S Lopez 4, Jose-Miguel Yamal 5 and Sara S Strom 3
Ludwig et al. BMC Cancer (2015) 15:190 DOI 10.1186/s12885-015-1180-6 RESEARCH ARTICLE Open Access The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk
More informationNEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING
NEOADJUVANT ENDOCRINE THERAPY PRIOR TO NERVE-SPARING RADICAL PROSTATECTOMY IN PATIENTS WITH STAGE T2 PROSTATIC CANCER Takeshi Uedal, Hiroomi Nakatsul, Shigeo Isaka2 and Jun Shimazaki2 1Urology, Kumagaya
More informationANTICANCER RESEARCH 26: (2006)
Low Pre-radiotherapy Prostate-specific Antigen Level is a Significant Predictor of Treatment Success for Postoperative Radiotherapy in Patients with Prostate Cancer TOMONARI SASAKI 1, KATSUMASA NAKAMURA
More informationOriginal Article. Cancer September 15,
Gleason Pattern 5 Is the Strongest Pathologic Predictor of Recurrence, Metastasis, and Prostate Cancer-Specific Death in Patients Receiving Salvage Radiation Therapy Following Radical Prostatectomy William
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationHow Should WeTreat Patients with Locally Advanced Prostate Cancer?
European Urology Supplements European Urology Supplements 2 (2003) 14 22 How Should WeTreat Patients with Locally Advanced Prostate Cancer? Malcolm Mason * Section of Oncology and Palliative Medicine,
More informationdiagnosed by transrectal needle biopsy who completed 3DCRT alone be- Center, Philadelphia, Pennsylvania.
75 Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy Steven R. Bonin, M.D. 1 BACKGROUND.
More informationWORLD JOURNAL OF SURGICAL ONCOLOGY
Koie et al. World Journal of Surgical Oncology 2014, 12:134 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine
More informationAdjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional survey study of the JROSG
Journal of Radiation Research, 2014, 55, 533 540 doi: 10.1093/jrr/rrt137 Advance Access Publication 1 January 2014 Adjuvant radiotherapy after prostatectomy for prostate cancer in Japan: a multi-institutional
More informationDelaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures
Eur Urol 2001;40(suppl 2):17 23 Delaying/Reducing the Risk of Clinical Tumour Progression after Primary Curative Procedures M. Wirth Department of Urology, Technical University of Dresden, Germany Key
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationYuzuru Niibe 1, Katsuyuki Karasawa 1, Toshio Mitsuhashi 2 and Yoshiaki Tanaka 3 INTRODUCTION. Jpn J Clin Oncol 2003;33(9)
Jpn J Clin Oncol 2003;33(9)450 455 Hyperfractionated Radiation Therapy for Hypopharyngeal Carcinoma Compared with Conventional Radiation Therapy: Local Control, Laryngeal Preservation and Overall Survival
More informationHORMONAL THERAPY COMBINED WITH RADIOTHERAPY IN LOCALLY ADVANCED PROSTATE CANCER
HORMONAL THERAPY COMBINED WITH RADIOTHERAPY IN LOCALLY ADVANCED PROSTATE CANCER Piotr Milecki 1, Zbigniew Kwias 2 1 Department of Radiotherapy, Great Poland Cancer Centre, ul. Garbary St. 15, 61-866 Poznań,
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationChanges in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer
Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer S Egawa 1 *, H Okusa 1, K Matsumoto 1, K Suyama 1 & S Baba 1 1 Department
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationTime to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment
Original paper Clinical Investigations Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment Al V. Taira, MD 1, Gregory S. Merrick, MD
More informationFive-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK
Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK Peter D. Dickinson*, Jahangeer Malik, Paula Mandall*, Ric Swindell*, David Bottomley,
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationGregor Habl 1,2*, Sonja Katayama 1, Matthias Uhl 1, Kerstin A. Kessel 1,2, Lutz Edler 3, Juergen Debus 1, Klaus Herfarth 1 and Florian Sterzing 1
Habl et al. BMC Cancer (2015) 15:868 DOI 10.1186/s12885-015-1886-5 RESEARCH ARTICLE Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationBiochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy
Yonago Acta medica 2016;59:288 295 Original Article Biochemical Recurrence Prediction in High-Risk Prostate Cancer Patients, Following Robot-Assisted Radical Prostatectomy Noriya Yamaguchi,* Tetsuya Yumioka,*
More informationProstate stem cell antigen mrna in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer
, 2018, Vol. 9, (No. 41), pp: 26291-26298 Prostate stem cell antigen mrna in blood is a predictor of survival after radical prostatectomy in patients with high-risk prostate cancer Yoon Seok Suh 1,*, Jae
More informationErectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer. William M. Mendenhall, MD
Erectile Dysfunction (ED) after Radiotherapy (RT) for Prostate Cancer William M. Mendenhall, MD Meta-Analysis of Probability of Maintaining Erectile Function after Treatment of Localized Cancer Treatment
More informationHigh-Risk Prostate Cancer: Local Therapy Matters
prostate cancer High-Risk Prostate Cancer: Local Therapy Matters Adam L. Liss, MD, and Daniel A. Hamstra, MD, PhD The second in a series of two articles on radiation and prostate cancer. See the May issue
More informationTreatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, VOLUME 7, NUMBER 4, FALL 2006 Treatment of exceptionally large prostate cancer patients with low-energy intensity-modulated photons Mei Sun and Lijun Ma a University
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationOutcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan
DOI: 10.1111/j.1745-7262.2006.00175.x www.asiaandro.com. Original Article. Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan Toshihiro Saito 1, Yasuo Kitamura
More informationEUROPEAN UROLOGY 62 (2012)
EUROPEAN UROLOGY 62 (2012) 472 487 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Judd W. Moul on pp. 488 490 of this issue
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationReceived June 2, 2006
NEOPLASMA 54, 1, 2007 7 Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain
More informationImpact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis
Original Article Yonsei Med J 218 Jul;59(5):58-587 pissn: 513-5796 eissn: 1976-2437 Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationKey words: prostatic neoplasms, risk groups, biochemical recurrence, clinical progression, prostate cancer specific mortality
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2016, 46(8) 762 767 doi: 10.1093/jjco/hyw061 Advance Access Publication Date: 20 May 2016 Original Article Original Article
More informationINTRODUCTION PATIENTS AND METHODS. Jpn J Clin Oncol 2007;37(10) doi: /jjco/hym098
Jpn J Clin Oncol 2007;37(10)775 781 doi:10.1093/jjco/hym098 Current Status of Endocrine Therapy for Prostate Cancer in Japan Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationClinical Study Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
Advances in Urology Volume 2012, Article ID 368528, 8 pages doi:10.1155/2012/368528 Clinical Study Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer Valérie
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationA comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients
ONCOLOGY LETTERS 14: 299-305, 2017 A comparison of clinicopathological features and prognosis in prostate cancer between atomic bomb survivors and control patients KOICHI SHOJI 1, JUN TEISHIMA 1, TETSUTARO
More informationCorey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*
Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationA retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured
Meijer et al. Radiation Oncology 2013, 8:190 RESEARCH Open Access A retrospective analysis of the prognosis of prostate cancer patients with lymph node involvement on MR lymphography: who might be cured
More informationJAMA. 1998;280:
Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More information